CARDINAL HEALTH INC
CAHAPI behind this page
CAH Q1 2026 request
Playground key active
/api/financials?ticker=CAH&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 64,009 | 52,277 | +22.4% |
Show Business Segments breakouts |
|||
| All Other Segments · at-Home Solutions [Member] | 1,115 | 739 | +50.9% |
| All Other Segments · Nuclear and Precision Health Solutions [Member] | 436 | 373 | +16.9% |
| All Other Segments · Operating Segments | 1,641 | 1,186 | +38.4% |
| All Other Segments · OptiFreight [Member] | 90 | 74 | +21.6% |
| GMPD · Operating Segments | 3,184 | 3,123 | +2.0% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 59,205 | 47,990 | +23.4% |
Show Geography breakouts |
|||
| Non Us | 419 | 408 | +2.7% |
| US | 63,611 | 51,891 | +22.6% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -21 | -22 | +4.5% |
| Operating Segments | 64,030 | 52,299 | +22.4% |
| Cost of Revenue | 61,690 | 50,375 | +22.5% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 1,221 | 884 | +38.1% |
| GMPD · Operating Segments | 2,633 | 2,604 | +1.1% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 57,857 | 46,909 | +23.3% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 61,711 | 50,397 | +22.4% |
| Gross Profit | 2,319 | 1,902 | +21.9% |
| Selling, General & Administrative | 1,461 | 1,277 | +14.4% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 254 | 198 | +28.3% |
| GMPD · Operating Segments | 505 | 511 | -1.2% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 681 | 551 | +23.6% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 1,440 | 1,260 | +14.3% |
| Restructuring Charges | 20 | 24 | -16.7% |
| Amortizationandotheracquisitionrelatedcosts | 104 | 74 | +40.5% |
| Acquisition Related Cash And Share Based Compensation Costs | 64 | — | — |
| Gain Loss On Sales Of Assets And Asset Impairment Charges | 2 | -1 | +300.0% |
| Operating Income | 668 | 568 | +17.6% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 166 | 104 | +59.6% |
| GMPD · Operating Segments | 46 | 8 | +475.0% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 667 | 530 | +25.8% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -211 | -74 | -185.1% |
| Operating Segments | 879 | 642 | +36.9% |
| Other Non-Operating Income (Expense) | -10 | -5 | -100.0% |
| Interest Expense | 80 | 32 | +150.0% |
| Income Before Taxes | 598 | 541 | +10.5% |
| Income Tax Expense (Benefit) | 144 | 124 | +16.1% |
| Net Income | 454 | 417 | +8.9% |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | 4 | 1 | +300.0% |
| Net Income Loss Attributable To Noncontrolling Interest | -4 | -1 | -300.0% |
| Net Income | 450 | 416 | +8.2% |
| EPS (Basic) | 1.89 | 1.71 | +10.5% |
| EPS (Diluted) | 1.88 | 1.7 | +10.6% |
| Wtd Avg Shares (Basic) | 238 | 243 | -2.1% |
| Wtd Avg Shares (Diluted) | 239 | 245 | -2.4% |
| Common Stock Dividends Per Share Declared | 0.51 | 0.51 | +1.0% |
| Total Costs & Expenses (Q) | — | — | — |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 1,475 | 1,082 | +36.3% |
| GMPD · Operating Segments | 3,138 | 3,115 | +0.7% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 58,538 | 47,460 | +23.3% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 63,151 | 51,657 | +22.3% |
| Comprehensive Income | 446 | 428 | +4.2% |
| Other Comprehensive Income | -4 | 12 | -133.3% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -4 | 12 | -133.3% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 4,593 | 2,867 | +60.2% |
| Receivables Net Current | 13,770 | 11,781 | +16.9% |
| Inventory | 17,559 | 15,619 | +12.4% |
| Other Assets Current | 2,602 | 2,591 | +0.4% |
| Assets Of Disposal Group Including Discontinued Operation | 13 | 47 | -72.3% |
| Total Current Assets | 38,537 | 32,905 | +17.1% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,831 | — | — |
Show Geography breakouts |
|||
| Non Us | 435 | — | — |
| US | 2,396 | — | — |
| Other Non-Current Assets | 1,750 | 1,231 | +42.2% |
| Total Assets | 55,228 | — | — |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 4,049 | — | — |
| GMPD · Operating Segments | 7,133 | — | — |
| Pharmaceutical and Specialty Solutions · Operating Segments | 38,683 | — | — |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 760 | — | — |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 5,363 | — | — |
| Goodwill | 9,711 | — | — |
Show Business Segments breakouts |
|||
| All Other Segments | 1,745 | — | — |
| Pharmaceutical and Specialty Solutions | 7,966 | — | — |
Show Business Acquisition breakouts |
|||
| ADS | 575 | — | — |
| Intangible Assets | 2,385 | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Relationships | 1,181 | — | — |
| Developed Technology Rights | 292 | — | — |
| Noncompete Agreements | 49 | — | — |
| Trademarks, trade names and patents | 863 | — | — |
| Other Assets | |||
| Intangible Assets Net Including Goodwill | 12,110 | 6,388 | +89.6% |
| Current Liabilities | |||
| Accounts Payable | 36,860 | 30,365 | +21.4% |
| Long Term Debt And Capital Lease Obligations Current | 52 | — | — |
| Other Accrued Liabilities Current | 3,356 | 3,373 | -0.5% |
| Total Current Liabilities | 40,268 | 34,678 | +16.1% |
| Non-Current Liabilities | |||
| Deferred Tax And Other Liabilities Noncurrent | 8,711 | 7,433 | +17.2% |
| Total Liabilities (Q) | — | — | — |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 620 | — | — |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 8,980 | — | — |
| Stockholders' Equity | |||
| Preferred Stock Shares Authorized | 500 | 500 | 0.0% |
| Common Stock Shares Authorized | 755 | 755 | 0.0% |
| Common Stock Shares Issued | 271 | 327 | -17.1% |
Show Equity Components breakouts |
|||
| Common Stock | 271 | 327 | -17.1% |
| Common Stock | 2,746 | 2,827 | -2.9% |
| Retained Earnings | 1,116 | 14 | +7871.4% |
| Treasury Stock Value | -6,582 | -5,963 | -10.4% |
| Treasury Stock Common Shares | 33 | 85 | -61.2% |
Show Equity Components breakouts |
|||
| Treasury Stock Common | 33 | 85 | -61.2% |
| Accumulated Other Comprehensive Income | -159 | -155 | -2.6% |
| Total Stockholders' Equity | -2,879 | -3,277 | +12.1% |
| Minority Interest | 148 | 1 | +14700.0% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -2,731 | -3,276 | +16.6% |
Show Equity Components breakouts |
|||
| Accumulated Foreign Currency Adjustment Including Portion Attributable To Noncontrolling Interest | -145 | -133 | -9.0% |
| Accumulated Gain Loss Net Cash Flow Hedge Noncontrolling Interest | -14 | -22 | +36.4% |
| Accumulated Other Comprehensive Income | -159 | -155 | -2.6% |
| Aoci Including Portion Attributable To Noncontrolling Interest | -159 | -155 | -2.6% |
| Common Stock | 2,746 | 2,827 | -2.9% |
| Noncontrolling Interest | 148 | 1 | +14700.0% |
| Retained Earnings | 1,116 | 14 | +7871.4% |
| Total Liabilities & Equity | 55,228 | 43,059 | +28.3% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 233 | 182 | +28.0% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 29 | 18 | +61.1% |
| GMPD · Operating Segments | 55 | 49 | +12.2% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 61 | 27 | +125.9% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 88 | 88 | 0.0% |
| Gain Loss On Sale Of Investments | 5 | 1 | +400.0% |
| Stock-Based Compensation | 93 | 30 | +210.0% |
| Provision For Doubtful Accounts | 13 | 16 | -18.8% |
| Increase Decrease In Receivables | -539 | 288 | -287.2% |
| Change in Inventory | -736 | -678 | -8.6% |
| Change in Accounts Payable | 2,147 | -1,394 | +254.0% |
| Increase Decrease In Other Operating Capital Net | -699 | -508 | -37.6% |
| Net Cash from Operations | 973 | -1,647 | +159.1% |
| Investing Activities | |||
| Capital Expenditures | -108 | -90 | -20.0% |
| Payments To Acquire Businesses Net Of Cash Acquired | -41 | — | — |
| Increase Decrease In Other Investing Items Net | 7 | 2 | +250.0% |
| Net Cash from Investing | -142 | -88 | -61.4% |
| Financing Activities | |||
| Proceeds From Debt Net Of Issuance Costs | 989 | — | — |
| Repayments Of Long Term Debt | -512 | -9 | -5588.9% |
| Payments To Minority Shareholders | 3 | — | — |
Show Equity Components breakouts |
|||
| GIA | -3 | — | — |
| Netproceedstaxwithholdingsfromsharebasedcompensation | -80 | -28 | -185.7% |
| Payments Of Dividends Common Stock | -129 | -128 | -0.8% |
| Share Repurchases | -375 | -375 | 0.0% |
Show Equity Components breakouts |
|||
| Common Stock | -75 | -75 | 0.0% |
Show Share Repurchase Program breakouts |
|||
| #375 million share repurchase program | -375 | -375 | 0.0% |
| Net Cash from Financing | -110 | -540 | +79.6% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -2 | 9 | -122.2% |
| Net Change in Cash | 719 | -2,266 | +131.7% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 4,593 | 2,867 | +60.2% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.